JP Morgan Maintains Neutral on Vir Biotechnology, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains a Neutral rating on Vir Biotechnology (NASDAQ:VIR) and raises the price target from $10 to $12.
May 03, 2024 | 7:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Eric Joseph maintains a Neutral rating on Vir Biotechnology and raises the price target from $10 to $12.
The increase in price target by JP Morgan suggests a positive outlook on the stock's value, potentially leading to short-term investor optimism and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90